As of the latest Form 4 filed Jun 30, 2026.
What Beta Bionics, Inc. Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 36 most recent filings for BBNX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 2026-06-29 | Feider Stephen Chief Financial Officer | SSale | −4.90K | $17.03 | $83.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Feider Stephen, Chief Financial Officer | MExercise | +4.90K | $5.10 | $25.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Feider Stephen, Chief Financial Officer | SSale | −5.10K | $17.05 | $87.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Feider Stephen, Chief Financial Officer | MExercise | +4.98K | $5.10 | $25.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-24 | Hopman Mark Chief Commercial Officer | SSale | −1.26K | $15.01 | $18.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-24 | Jones Christy Director | SSale | −1.41K | $15.00 | $21.1K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Hopman Mark Chief Commercial Officer | SSale | −275.00 | $12.31 | $3.39K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Jones Christy Director | SSale | −2.81K | $14.00 | $39.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-02 | Russell Steven Jon Chief Medical Officer | SSale | −4.22K | $12.61 | $53.2K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-02 | Saint Sean President & CEO | SSale | −16.9K | $12.61 | $213K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-02 | Feider Stephen Chief Financial Officer | SSale | −6.68K | $12.61 | $84.2K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-02 | Mensinger Mike Chief Product Officer | SSale | −4.38K | $12.61 | $55.2K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-02 | Hopman Mark Chief Commercial Officer | SSale | −5.33K | $12.61 | $67.2K | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-22 | Lezack Adam Director | SSale | −998.00 | $11.21 | $11.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Jones Christy Director | AAward | +17.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Jones Christy, Director | SSale | −2.00K | $9.95 | $19.9K | Yes (planned) | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Lezack Adam Director | AAward | +17.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Lezack Adam, Director | SSale | −1.00K | $9.95 | $9.95K | Yes (planned) | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Palasis Maria Director | AAward | +17.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Dearen Danny L. Director | AAward | +17.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | CARNEY SEAN Director | AAward | +17.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | MICHEL GERARD J Director | AAward | +17.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2025-12-04 | Hopman Mark Chief Commercial Officer | SSale | −2.06K | $30.66 | $63.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-16 | 2025-12-02 | Russell Steven Jon Chief Medical Officer | SSale | −1.02K | $29.34 | $30.1K | No | Form 4 ↗ |
| 2026-03-16 | 2025-12-02 | Hopman Mark Chief Commercial Officer | SSale | −856.00 | $29.34 | $25.1K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-04 | Hopman Mark Chief Commercial Officer | SSale | −353.00 | $11.57 | $4.08K | Yes (planned) | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Russell Steven Jon Chief Medical Officer | SSale | −1.03K | $12.36 | $12.7K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Saint Sean President & CEO | SSale | −3.38K | $12.36 | $41.8K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Feider Stephen Chief Financial Officer | SSale | −1.43K | $12.36 | $17.7K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Mensinger Mike Chief Product Officer | SSale | −1.06K | $12.36 | $13.2K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Hopman Mark Chief Commercial Officer | SSale | −834.00 | $12.36 | $10.3K | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Russell Steven Jon Chief Medical Officer | AAward | +109K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Saint Sean President & CEO | AAward | +343K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Feider Stephen Chief Financial Officer | AAward | +132K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Mensinger Mike Chief Product Officer | AAward | +109K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Hopman Mark Chief Commercial Officer | AAward | +109K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also BBNX’s full analysis or the market-wide insider trading feed. The tabs above jump to BBNX’s other SEC data.
Source: SEC Form 4 filings for BBNX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.